Name: In Vivo Star Anti-Mouse CD25 (IL-2Rα) Antibody
Brand: InnoCyto
SKU: 508901
Price: 160 USD
Availability: InStock

Shop Now Contact

In Vivo Star Anti-Mouse CD25 (IL-2Rα) Antibody

InnoCyto Product Image

Cat #	Size	Price
508901	1 mg	$160
508902	5 mg	$400
508903	25 mg	$1100

Bulk/Custom

Product Details

Clone	PC61.5.3-m2c
Application	ELISA, WB, Flow cytometry, IHC, ICC, animal model study
Host Species	CHO cells
Reactivity	Mouse
Format	Liquid
Target Name	IL-2 receptor α chain, Low affinity IL-2R, IL-2Rα chain
Product Description	In vivo Grade Recombinant Anti-mouse CD25 Monoclonal Antibody
Isotype	Mouse IgG2c Kappa
Antibody Type	Recombinant
Regulatory Status	RUO
Purity	>95% by reducing SDS-PAGE
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions	4ºC
Grade	In vivo
Recommended Usage	This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
RRID	AB_3739363
Research Areas	T cells, Tregs, T cell Activation, Adaptive Immunity, Autoimmunity, Cancer Marker, Dendritic cells
See All Formats	Clone PC61.5.3-m2c

Background Information

CD25, also known as the interleukin-2 receptor alpha chain (IL-2Rα), is a transmembrane glycoprotein that plays a central role in regulating immune responses. It functions as part of the interleukin-2 (IL-2) receptor complex, which is essential for T cell proliferation, survival, and differentiation. CD25 itself has low affinity for IL-2 when expressed alone, but when combined with IL-2 receptor beta (CD122) and the common gamma chain (CD132), it forms the high-affinity IL-2 receptor complex capable of effective signal transduction.

Structurally, CD25 is a single-pass type I membrane protein composed of an extracellular domain of approximately 219 amino acids responsible for IL-2 binding, a hydrophobic transmembrane segment, and a short cytoplasmic tail that lacks intrinsic signaling domains. The extracellular region is heavily glycosylated, which stabilizes its conformation and facilitates ligand interaction. Because the alpha chain alone is not signaling-competent, it acts primarily to increase the receptor complex’s affinity for IL-2 and to expand the range of cells responsive to low cytokine concentrations.

CD25’s main ligand, IL-2, is a cytokine crucial for T lymphocyte expansion and immune tolerance. Engagement of IL-2 with the high-affinity receptor triggers the JAK-STAT signaling pathway, leading to cell proliferation, differentiation, and regulatory T cell (Treg) function. CD25 is constitutively expressed on Tregs and upregulated on activated CD4+ and CD8+ T cells, making it a marker of immune activation as well as immune regulation.

Aberrant CD25 expression or IL-2 signaling contributes to immune dysregulation and disease. In autoimmune disorders such as multiple sclerosis and type 1 diabetes, alterations in the IL-2/CD25 axis impair Treg function and tolerance mechanisms. Elevated CD25 expression is also found in certain malignancies, particularly adult T-cell leukemia/lymphoma and Hodgkin lymphoma, where it may serve as a biomarker of malignant proliferation. Moreover, soluble CD25, released from cell surfaces, can act as a decoy receptor, modulating IL-2 availability and contributing to immune suppression in cancer and chronic inflammation.

Therapeutically, CD25 is a prominent target for immune modulation. Monoclonal antibodies such as basiliximab and daclizumab have been developed to block IL-2 binding, preventing T cell activation and mitigating graft rejection in organ transplantation. Conversely, IL-2 or CD25-targeted therapies that enhance regulatory T cell function are being explored to treat autoimmune diseases and promote immune tolerance. Thus, CD25 remains a critical immunological node, balancing activation and regulation within the immune system.

Frequently Asked Questions

What are In Vivo Star Biofunctional Antibodies?

In Vivo Star antibodies are premium-grade monoclonal antibodies purified and formulated specifically for use in animal studies. Each lot is manufactured under stringent quality controls to ensure the low endotoxin levels, high purity, and functional activity required for reliable in vivo results.

How are these antibodies different from standard research antibodies (e.g., for Western blot or flow cytometry)?

Standard research antibodies are optimized for in vitro detection assays and may contain preservatives, carrier proteins (like BSA), or higher endotoxin levels unsuitable for injection. In Vivo Star antibodies are formulated in injectable-grade, azide-free, low-endotoxin buffers and validated for functional bioactivity in living systems rather than just antigen binding.

What endotoxin and purity specifications do these antibodies meet?

All In Vivo Star antibodies are tested and certified to meet low-endotoxin thresholds (typically <1 EU/mg, lot-dependent) using the LAL (Limulus Amebocyte Lysate) assay, and are purified to ≥95% purity by SEC-HPLC or SDS-PAGE. Exact specifications are provided on the Certificate of Analysis (CoA) for each lot.

Are these antibodies azide-free and carrier-free?

All In Vivo Star antibodies are formulated without sodium azide and without carrier proteins such as BSA or gelatin, since both can interfere with animal physiology or immune readouts during in vivo studies.

Do you provide isotype controls?

Matched isotype control antibodies (same host species, isotype, and formulation) are available upon request for most clones to support proper experimental controls.

How should In Vivo Star antibodies be stored and handled?

Store at 4°C for short-term use and avoid repeated freeze-thaw cycles, which can reduce bioactivity; aliquoting is recommended for long-term storage per the product-specific storage instructions on the Certificate of Analysis. Always confirm storage conditions and expiration on the CoA that accompanies each lot, as these can vary slightly by antibody.

Have a product or application question? Consult our FAQs or contact us.

Search Tips